Abstracts tagged "SLE"

Abstract Number: 1816 • 2016 ACR/ARHP Annual Meeting
SLE and Uctd in the Rheumatology Informatics System for Effectiveness (RISE) Registry
Julia F Simard¹, Jim Oates², Jinoos Yazdany³, Nick Bansback⁴, Deborah Collier⁵, Karen Law⁶, Katherine Liao⁷, Kaleb Michaud⁸, Esi Morgan⁹, Catalina Orozco¹⁰, Andreas Reimold¹¹, Rachel Myslinski¹², Tracy Johansson¹³, Salahuddin Kazi¹⁴ and Megan E. B. Clowse¹⁵, ¹Division of Epidemiology, Health Research and Policy Department, and Division of Immunology & Rheumatology, Department of Medicine, Stanford School of Medicine, Stanford, CA, ²Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ³Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁴Population and Public Health, The University of British Columbia, Vancouver, BC, Canada, ⁵Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁶Internal Medicine, Emory University School of Medicine, Atlanta, GA, ⁷Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, ⁸University of Nebraska Medical Center, Omaha, NE, ⁹Pediatric rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁰Rheumatology Associates, Dallas, TX, ¹¹Hospital of Southern Norway, Kristiansand, Norway, ¹²Governance & Ethics Specialist, Amer College of Rheumatology, Atlanta, GA, ¹³Practice, Advocacy & Quality, American College of Rheumatology, Atlanta, GA, ¹⁴Rheumatology, UT Southwestern Medical Center, Dallas, TX, ¹⁵Rheumatology, Duke University School of Medicine, Durham, NC
Background/Purpose: The ACR-sponsored RISE (Rheumatology Informatics System for Effectiveness) Registry is an electronic health record (EHR)-based national database of rheumatology clinical visits. De-identified patient data…
Abstract Number: 2810 • 2016 ACR/ARHP Annual Meeting
Correlates of Spontaneous Cytokine Production in Individuals Undergoing Interferon-Gamma Release Assay Testing
Grant Hughes¹, Christian Lood², Uche Obih¹ and David Koelle¹, ¹University of Washington, Seattle, WA, ²Department of Medicine, Division of Rheumatology, University of Washington, Seattle, WA
Background/Purpose: The interferon gamma (IFN-G) release assay (IGRA) estimates probability of latent TB infection (LTBI) based on IFN-G released by whole blood after 18h exposure…
Abstract Number: 2936 • 2016 ACR/ARHP Annual Meeting
All-Trans Retinoic Acid Stabilizes Natural T Regulatory Cells Isolated from Patients with Systemic Lupus Erythematosus Under Inflammatory Conditions
Julie Wang¹, Zixuan Qiao², Feng Huang³, Ya Liu², Nancy J. Olsen⁴ and Song Guo Zheng⁵, ¹Medicine, Penn State Hershey Medical Center, Hershey, PA, ²Medicine, Xuzhou Medical University, Xuzhou, China, ³Center for Clinic Immunology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Guangzhou, China, ⁴Medicine/Rheumatology, Penn State Hershey Medical Center, Hershey, PA, ⁵Medicine/Rheumatology, Penn State University Hershey Medical Center, Hershey, PA
Background/Purpose: Recent studies have demonstrated that naturally occurring CD4+Foxp3+regulatory T cells (nTregs) are unstable and dysfunctional in the presence of pro-inflammatory cytokines. All-trans RA (atRA),…
Abstract Number: 121 • 2016 ACR/ARHP Annual Meeting
Systemic Lupus Erythematosus (SLE) Is a Salient Cause of Premature Mortality in the United States: A Sex-Based Exploration
Titilola Falasinnu¹ and Julia F Simard², ¹Health Research and Policy, Stanford University, Stanford, CA, ²Division of Epidemiology, Health Research and Policy Department, and Division of Immunology & Rheumatology, Department of Medicine, Stanford School of Medicine, Stanford, CA
Background/Purpose: The epidemiology of SLE has a complex gendered aspect, characterized by marked differences between the sexes in terms of the incidence, prevalence, and clinical…
Abstract Number: 965 • 2016 ACR/ARHP Annual Meeting
Clinical and Serologic Variables Associated with Renal Response Among Lupus Nephritis Phase III Trial Patients Treated with Standard of Care Immunosuppression
Matthew D. Cascino¹, Peter Lambert², Anna Decker², Tamiko Katsumoto², Jay Garg², Paul Brunetta², Maria Dall'Era¹ and Leonard L. Dragone², ¹Division of Rheumatology, University of California, San Francisco, San Francisco, CA, ²Genentech, Inc., South San Francisco, CA
Background/Purpose: Lupus nephritis (LN) is associated with high treatment failure rates and the development of new therapies for LN is limited by the lack of…
Abstract Number: 1384 • 2016 ACR/ARHP Annual Meeting
Comparison of the Systemic Lupus Collaborating Clinics-Damage Index Score with a Physician Global Assessment of Damage in an International Cohort of Patients with Childhood-Onset Systemic Lupus
Michael J. Holland¹, Jun Ying², Nicolino Ruperto^3,4, Kasha Wiley¹, Earl Silverman⁵ and Hermine I. Brunner¹, ¹Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Center for Biostatistical Services, University of Cincinnati College of Medicine, Cincinnati, OH, ³Pediatria II, Reumatologia, Istituto Giannina Gaslini, Genoa, Italy, ⁴Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genoa, Italy, ⁵Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) is a chronic autoimmune disease, which can affect any organ system. cSLE is associated with significant morbidity, including…
Abstract Number: 1817 • 2016 ACR/ARHP Annual Meeting
A Longitudinal Analysis of Change in Lupus Disease Activity Pattern in Hopkins Lupus Cohort Using a Multistate Markov Model Approach
Wei Fu¹ and Michelle Petri², ¹Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a multi-systemic inflammatory disease with extreme variability of its activity over time. We have described three main patterns: long…
Abstract Number: 2811 • 2016 ACR/ARHP Annual Meeting
Predictors of Persistent Disease Activity and Persistent Remission in Systemic Lupus Erythematosus – Results from the Hopkins Lupus Cohort
Ioanna Giannakou¹, Katerina Chatzidionysiou², Noémi Györi³, Laurence S Magder⁴, Ronald F. van Vollenhoven^5,6 and Michelle Petri⁷, ¹Department of Medicine, Karolinska Institute, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Department of Medicine, Karolinska Institute, Stockholm, Sweden, ²Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Department of Medicine, Karolinska Institute, Stockholm, Sweden, ³Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Department of Medicine, Karolinska Institute, Stockholm, Sweden, ⁴Epidemiology and Public Health, Division of Rheumatology, School of Medicine, Johns Hopkins University, Baltimore, MD, ⁵Rheumatology Unit, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Department of Medicine, Karolinska Institute, Stockholm, Sweden, ⁶Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, ⁷Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by a variability of disease expression, both between individuals and within individuals, over time. The aim of this…
Abstract Number: 2937 • 2016 ACR/ARHP Annual Meeting
Regulation of Follicular Helper T (TFH) Cells By ROCK2 (Rho-associated coiled-coil containing protein kinase 2)
Woelsung Yi¹, Sanjay Gupta², Chien-Huan Weng³, Yurii Chinenov⁴, James K. Liao⁵ and Alessandra B. Pernis⁶, ¹Hospital for Special Surgery, New York, NY, ²Autoimmunity & Inflammation Research Program, Hospital for Special Surgery, New York, NY, ³Weill Cornell Medical College, New York, NY, ⁴Arthritis & Tissue Degeneration Program, Hospital for Special Surgery, New York, NY, ⁵Cardiology Section, University of Chicago Medical Center, Chicago, IL, ⁶David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY
Background/Purpose: Follicular helper T (TFH) cells promote humoral responses and serve as a limiting factor for the selection of high affinity germinal center B cells.…
Abstract Number: 122 • 2016 ACR/ARHP Annual Meeting
A Small Number of Patients with SLE Account for Most of the Direct and Indirect Hospitalization Costs
Allen P. Anandarajah¹, Bethany A. Marston², Debbie Campbell³ and Christopher T. Ritchlin⁴, ¹Dept of Rheumatology, Univ of Rochester Med Ctr, Rochester, NY, ²Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ³Allergy, Immunology & Rheumatology, University of Rochester, Rochester, NY, ⁴Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that can affect multiple organ systems and is associated with high morbidity. Studies have shown…
Abstract Number: 966 • 2016 ACR/ARHP Annual Meeting
Renal Activity in Lupus (RAIL) Urinary Biomarkers Predict Treatment Response
Gaurav Gulati¹, Michael Bennett², Khalid Abulaban^3,4, Qing Ma⁵, Marisa S. Klein-Gitelman⁶, Kelly A. Rouster-Stevens⁷, Christopher Haffner⁵, Kasha Wiley⁸, Stacy P. Ardoin⁹, Jun Ying¹⁰, Prasad Devarajan¹¹ and Hermine I. Brunner⁸, ¹Division of Immunology, Allergy and Rheumatology, University of Cincinnati College of Medicine, Cincinnati, OH, ²Division of Nephrology, Cincinnati Children`s Hospital Medical Center, Cincinnati, OH, ³Department of Pediatrics, Division of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁴Pediatric Rheumatology, Helen DeVos Children's Hospital, Grand Rapids, MI, ⁵Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, ⁶Div of Pediatric Rheumatology/PDD PTD, Lurie Children's Hospital of Chicago/NW University, Chicago, IL, ⁷Pediatric Rheumatology, Emory Children's Center, Atlanta, GA, ⁸Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹Pediatric & Adult Rheumatology, Ohio State University, Columbus, OH, ¹⁰Center for Biostatistical Services, University of Cincinnati College of Medicine, Cincinnati, OH, ¹¹Dept of Nephrology, Cincinnati Children`s Hospital Medical Center, Cincinnati, OH
Renal Activity In Lupus (RAIL) Urinary Biomarkers Predict Treatment Response Background/Purpose: We have previously demonstrated the strong predictive value of the Renal Activity In Lupus…
Abstract Number: 1387 • 2016 ACR/ARHP Annual Meeting
Evaluation of Mild to Moderate SLE Flare in Patients with Childhood-Onset Disease
Malki Peskin¹, Dawn Wahezi^2,3, Chaim Putterman⁴, Tamar Rubinstein^5,6 and Nicole Jordan^4,7, ¹Pediatrics, Albert Einstein College of Medicine, Bronx, NY, ²Pediatric Rheumatology, The Children's Hospital at Montefiore, Bronx, NY, ³Pediatric Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁴Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁵Pediatric Rheumatology, Children's Hospital at Montefiore, Bronx, NY, ⁶Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁷Montefiore Medical Center, New York, NY
Background/Purpose: One aspect of childhood SLE lacking understanding is the prediction of disease flares. The objective of this study is to identify predictors of mild…
Abstract Number: 1828 • 2016 ACR/ARHP Annual Meeting
Metabolic Reprogramming in CD4+CD28-CXCR3intt-bethi cells and Its Relevance to Pathogenesis in Patients with SLE
Shigeru Iwata¹, Yuka Kanno², Kei Sakata^3,4, Maiko Hajime¹, Masataka Torigoe^1,5, Naoaki Ohkubo¹, Shingo Nakayamada⁶, John J O'Shea⁷ and Yoshiya Tanaka⁸, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, ³Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan, ⁴The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyshu, Japan, ⁵Department of Endocrinology, Metabolism, Rheumatology and Nephrology,, Faculty of Medicine, Oita University, Yufu, Oita, Japan, Yufu, Japan, ⁶First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁷NIAMS NIH, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, ⁸University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: CD4+ T cells play a crucial role in pathological process of Systemic Lupus Erythematosus (SLE). Recently, importance of metabolic reprograming in immunocompetent cells was…
Abstract Number: 2815 • 2016 ACR/ARHP Annual Meeting
Comparison of Lupus Nephritis Induction Therapy with Cyclophosphamide High Dose Versus Low Dose
Juliana Valim¹, Verônica Lima², Fernanda Guimarães³, Fernanda Chaer⁴ and Branca Souza⁵, ¹Rheumatology, Santa Casa de São Paulo, São Paulo, Brazil, ²Rheumatology, Irmandade Santa Casa de São Paulo, São Paulo, Brazil, ³Rheumatology, Irmandade Santa Casa de Misericordia de São Paulo, São Paulo, Brazil, ⁴Rheumatology, Irmandade da Santa Casa de São Paulo, São Paulo, Brazil, ⁵Reumatologia, Irmandade da Santa Casa de Misericordia de São Paulo, São Paulo, Brazil
Background/Purpose: To Compare the induction therapy of lupus nephritis with cyclophosphamide (CYC) high dose or low dose and identify possible predictors of disease remission. Methods:…
Abstract Number: 2984 • 2016 ACR/ARHP Annual Meeting
Novel Anti-Malarial Drug Derivative Inhibited Type I Interferon Production and Autoimmune Inflammation through Inhibition of CGAS-Sting Pathway in Trex1-/- Mouse
Jie An¹, Joshua Woodward², Mark Minie³, Xizhang Sun⁴, Lena Tanaka¹, Yufeng Peng¹, Jessica Snyder⁴, Tomikazu Sasaki⁵ and Keith B. Elkon⁶, ¹Division of Rheumatology, University of Washington, Seattle, WA, ²Department of Microbiology, University of Washington, Seattle, WA, ³Department of Bioengineering, University of Washington, Seattle, WA, ⁴University of Washington, Seattle, WA, ⁵Department of Chemistry, University of Washington, Seattle, WA, ⁶Department of Medicine, Division of Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Type I interferon, (IFN-I) is strongly implicated in the pathogenesis of SLE as well as rare monogenic ‘interferonopathies’ such as Aicardi-Goutieres Syndrome (AGS) caused…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.